Connecticut 2019 Regular Session

Connecticut House Bill HB06154

Introduced
1/24/19  
Introduced
1/24/19  

Caption

An Act Prohibiting The Marketing Of Opioid Drugs And Distribution Of Samples Of Such Drugs.

Impact

If enacted, HB 6154 will amend the current statutes to explicitly ban the marketing of opioids, leading to a shift in how these drugs are promoted within the healthcare system. Consequently, prescribing practitioners will no longer receive promotional material intended to incentivize them to prescribe opioid medications. This legislative action is expected to help mitigate the influence of aggressive marketing tactics that have historically pressured healthcare providers into prescribing practices that contribute to the opioid epidemic.

Summary

House Bill 6154 aims to address the ongoing opioid crisis by prohibiting the marketing of opioid drugs to both prescribing practitioners and patients. The legislation recognizes the detrimental impact that marketing efforts can have on prescription practices and overall public health. This bill is a response to significant concerns regarding the role of pharmaceutical marketing in promoting the unnecessary or excessive prescribing of opioids, which has contributed to widespread addiction and overdose cases.

Contention

Despite the bill's well-meaning goals, some stakeholders may express concerns regarding its potential impact on the availability of information about opioid medications. Critics might argue that while the intention to reduce marketing is valid, a complete prohibition could limit valuable educational outreach that informs practitioners about safe prescribing practices and the appropriate use of opioids. Additionally, the pharmaceutical industry may resist this bill, fearing a loss of market access and communication with healthcare professionals.

Notable_points

Overall, HB 6154 reflects a growing recognition of the public health threat posed by opioid misuse and is part of broader efforts to reform prescribing practices and drug marketing. The bill underscores the importance of transitioning towards more responsible and ethical approaches to pharmaceutical promotion in order to protect patients and communities from the harmful effects of opioids.

Companion Bills

No companion bills found.

Previously Filed As

CT SB00274

An Act Concerning Opioids.

CT HB05249

An Act Concerning Personal Opioid Drug Deactivation And Disposal Systems And The Opioid Settlement Fund.

CT SB00133

An Act Concerning Regulation Of Prescription Drugs And Related Professions.

CT SB00202

An Act Concerning The Department Of Consumer Protection's Recommendations Regarding Prescription Drug Control.

CT SB00008

An Act Concerning Drug Affordability.

CT SB00182

An Act Prohibiting Certain Health Carriers From Requiring Step Therapy For Prescription Drugs Used To Treat A Mental Or Behavioral Health Condition Or A Chronic, Disabling Or Life-threatening Condition.

CT HB05291

An Act Concerning The Department Of Public Health's Recommendations Regarding Improved Opioid Monitoring.

CT HB05513

An Act Concerning The Deduction And Withholding Of Personal Income Tax From Certain Payments And Distributions.

CT HB05511

An Act Concerning The Opioid Settlement Advisory Committee.

CT SB00230

An Act Concerning Mailing Of Test Results Related To Operating A Motor Vehicle Or Vessel Under The Influence Of Alcohol Or Drugs.

Similar Bills

No similar bills found.